Rhythm Pharmaceuticals, Inc.
RYTM
$59.93
-$0.25-0.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.88% | 68.06% | 81.55% | 132.57% | 173.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.88% | 68.06% | 81.55% | 132.57% | 173.52% |
| Cost of Revenue | 32.95% | 43.72% | 80.57% | 119.97% | 221.54% |
| Gross Profit | 50.98% | 71.38% | 81.67% | 134.26% | 168.25% |
| SG&A Expenses | 17.07% | 22.78% | 24.29% | 29.84% | 33.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.10% | 15.83% | 15.56% | 22.61% | 27.58% |
| Operating Income | 3.73% | 6.10% | 6.52% | 4.06% | -0.17% |
| Income Before Tax | 38.26% | -41.34% | -39.48% | -41.62% | -51.22% |
| Income Tax Expenses | -85.53% | -38.83% | 71.47% | -- | -- |
| Earnings from Continuing Operations | 38.40% | -41.09% | -39.54% | -42.36% | -51.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.40% | -41.09% | -39.54% | -42.36% | -51.70% |
| EBIT | 3.73% | 6.10% | 6.52% | 4.06% | -0.17% |
| EBITDA | 3.67% | 6.05% | 6.48% | 4.02% | -0.22% |
| EPS Basic | 39.30% | -35.92% | -33.11% | -32.69% | -37.93% |
| Normalized Basic EPS | 11.65% | 13.91% | 15.50% | 14.80% | 7.64% |
| EPS Diluted | 39.30% | -35.92% | -33.11% | -32.69% | -37.93% |
| Normalized Diluted EPS | 11.65% | 13.91% | 15.50% | 14.80% | 7.64% |
| Average Basic Shares Outstanding | 5.46% | 5.77% | 6.07% | 7.67% | 8.98% |
| Average Diluted Shares Outstanding | 5.46% | 5.77% | 6.07% | 7.67% | 8.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |